A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
Phase 3
Completed
NCT05931380
| Condition | Obesity |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Eli Lilly and Company |
|---|
| Status | Completed |
|---|
| Enrollment | 238 participants |
|---|
| Interventions | Orforglipron |
|---|
| Start date | Jul 31, 2023 |
|---|
| Completion date | Jun 19, 2025 |
|---|
| Results posted | Jul 20, 2026 |
|---|
Summary
The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.
Percent Change From Baseline in Body Weight at Week 72
Baseline, Week 72 · percent change
| Placebo QD | -0.63 ± 0.732 percent change |
|---|
| 6 mg Orforglipron QD | -5.90 ± 0.866 percent change |
|---|
| 12 mg Orforglipron QD | -8.69 ± 1.136 percent change |
|---|
| 36 mg Orforglipron QD | -7.93 ± 1.063 percent change |
|---|
| p-value | <.001 |
|---|
| LS Mean Difference (Final values) | -5.28 (95% CI -7.52–-3.03) |
|---|
Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline
Baseline to Week 72 · Percentage of Participants
| Placebo QD | 15.00 Percentage of Participants |
|---|
| 6 mg Orforglipron QD | 45.90 Percentage of Participants |
|---|
| 12 mg Orforglipron QD | 61.40 Percentage of Participants |
|---|
| 36 mg Orforglipron QD | 58.33 Percentage of Participants |
|---|
| p-value | <.001 |
|---|
| Risk Difference (RD) | 30.36 (95% CI 15.09–45.62) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.